Kobari M, Egawa S, Shibuya K, Sunamura M, Saitoh K, Matsuno S
First Department of Surgery, Tohoku University School of Medicine, Sendai, Japan.
Br J Surg. 2000 Jan;87(1):43-8. doi: 10.1046/j.1365-2168.2000.01336.x.
The prognosis of patients with resected pancreatic cancer remains poor. This study evaluated the effect of adoptive immunotherapy (AIT) using intraportal infusion of lymphokine-activated killer (LAK) cells after curative resection and intraoperative radiation therapy (IORT) on advanced pancreatic cancer.
Twenty-nine consecutive patients with advanced pancreatic cancer (Japan Pancreas Society stage III or IV) were divided into two groups. The control group (n = 17) underwent tumour resection and IORT. The treatment group (n = 12) underwent resection, IORT and intraportal infusion of LAK cells combined with recombinant interleukin 2 (rIL-2). The incidence of liver metastasis and the survival rate of these two groups were compared.
Although the overall survival between groups was not statistically different (P = 0.082), there were more patients (four) alive 3 years after operation in the test group (36 per cent versus zero), and the incidence of liver metastases in the treatment group was significantly lower (three of 12 versus ten of 15; P < 0.05). LAK therapy influenced survival positively in multivariate analysis.
These preliminary observations suggest that AIT warrants further study as a possible adjuvant for patients undergoing curative resection and IORT for pancreatic cancer.
接受胰腺癌切除术患者的预后仍然较差。本研究评估了在根治性切除及术中放疗（IORT）后，经门静脉输注淋巴因子激活的杀伤细胞（LAK）进行过继性免疫治疗（AIT）对晚期胰腺癌的疗效。
连续纳入29例晚期胰腺癌患者（日本胰腺学会III期或IV期）并分为两组。对照组（n = 17）接受肿瘤切除及IORT。治疗组（n = 12）接受切除、IORT以及经门静脉输注LAK细胞联合重组白细胞介素2（rIL-2）。比较两组肝转移发生率及生存率。
尽管两组间总生存期无统计学差异（P = 0.082），但试验组术后3年仍存活的患者更多（4例）（36% 对0），且治疗组肝转移发生率显著更低（12例中的3例对15例中的10例；P < 0.05）。多因素分析显示LAK治疗对生存有积极影响。
这些初步观察结果表明，AIT作为接受胰腺癌根治性切除及IORT患者的一种可能辅助治疗手段，值得进一步研究。
